NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global gene therapy market size is estimated to grow by USD 6.74 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 23.31% during the forecast period. Increase in special drug designations is driving market growth, with a trend towards growing research in gene therapy for CVDs and orphan diseases.
However, high treatment cost poses a challenge.Key market players include Abeona Therapeutics Inc, Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc, Amgen Inc., Astellas Pharma Inc.
, Biogen Inc., bluebird bio Inc., Editas Medicine Inc.
, ElevateBio, F. Hoffmann La Roche Ltd., Generation Bio Co.
, Gilead Sciences Inc., Novartis AG, Orchard Therapeutics Plc, Poseida Therapeutics Inc., Sangamo Therapeutics Inc, Sibiono GeneTech Co.
Ltd., Syncona Ltd., uniQure NV, and Voyager Therapeutics Inc.
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The gene therapy market is experiencing significant growth due to the increasing prevalence of chronic diseases, particularly cardiovascular diseases (CVDs), and the need for effective and timely treatments. Major pharmaceutical companies are investing heavily in research and development (R&D) of novel gene therapies, particularly for diseases with a monogenic cause, such as many orphan diseases.
The aging popul.
